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Background: BRCC3 has been found to be aberrantly expressed in breast tumors and involved in DNA damage
response. The contribution of BRCC3 to nasopharyngeal carcinoma prognosis and radiosensitivity is still unclear.
Methods: Immunohistochemical analysis of BRCC3 was carried out in 100 nasopharyngeal carcinoma tissues, and
the protein level was correlated to patient survival. BRCC3 expression of nasopharyngeal carcinoma cell lines was
determined by Western-blotting and real-time PCR. Additionally, the effects of BRCC3 knockdown on nasopharyngeal
carcinoma cell clongenic survival, DNA damage repair, and cell cycle distribution after irradiation was assessed.
Results: The BRCC3 protein level was inversely correlated with nasopharyngeal carcinoma patient overall survival
(P < 0.001) and 3-year loco-regional relapse-free survival (P = 0.034). Multivariate analysis demonstrated that BRCC3
expression was an independent prognostic factor (P = 0.010). The expression of BRCC3 was much higher in
radioresistant nasopharyngeal carcinoma cells than in radiosensitive cells. Knockdown of BRCC3 increased the cell
survival fraction, attenuated DNA damage repair and resulted in G2/M cell cycle arrest in radioresistant NPC cells.
Conclusions: High BRCC3 expression in nasopharyngeal carcinoma patients is associated with poor survival. BRCC3
knockdown could abate the radioresistance in nasopharyngeal carcinoma cells. These findings suggest the utility of
BRCC3 as a prognostic biomarker and novel target for nasopharyngeal carcinoma.
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Nasopharyngeal carcinoma (NPC) is a form of epithelial
cancer with high occurrence rates in Southeast Asia and
southern China, where its incidence is approximately 25
to 50 cases per 100,000 individuals [1]. Radiotherapy has
been used as the primary treatment of nasopharyngeal
carcinoma [2], and a majority of NPC patients can be
cured when diagnosed and treated at an early disease
stage. However, approximately 20 % of NPC patients* Correspondence: xiayf@sysucc.org.cn
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diosensitivity is widely perceived as one of the major ob-
stacles for radiotherapy.
Investigators have made many efforts to understand the
DNA damage response(DDR). In this process, factors gath-
ered to sites of DNA damage within minutes of irradiation
[4–6], and initiated a phosphorylation signaling cascade.
Firstly, DNA damage induce ATM/ATR phosphorylation
on S139 of histone H2AX, then directly recruits MDC1
through its BRCT domains, and the phosphorylation of
MDC1 leads to the recruitment of an ubiquitin ligase
RNF8/UBC13 to damage sites. The subsequent ubiqutina-
tion events on the damaged chromatin create docking sites
for DNA repair proteins to accumulate at DNA double
strand breaks(DSBs) [7–11]. Following the resolution ofdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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Male 77 41 36 1.030 0.310a
Female 23 15 8
Age
<45 47 27 20 0.075 0.784 a
≥45 53 29 24
Histological
classification
Type II 8 5 3 0.149 0.699 b
Type III 92 51 41
Clinical stage
I-II 56 25 31 6.662 0.010 a *
III-IV 44 31 13
T
T1-T2 66 39 27 0.753 0.386 a
T3-T4 34 17 17
N
N0 60 39 21 4.931 0.026 a *
N1-N3 40 17 23
M
M0 83 52 31 8.764 0.003 a *
M1 17 4 13
Relapse
Yes 14 8 6 0.009 0.926 a
No 86 48 38
Skull-based invasion
Yes 20 11 9 0.010 0.920 a
No 80 45 35
a Pearson Chi-Square test (asymptotic significance, two-sided)
b Fisher’s exact test (two-sided)
* Significantly different
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alleviating cell cycle checkpoint responses and allowing re-
sumption of cell proliferation.
BRCA1-BRCA2-containing complex(BRCC), a novel
multiprotein complex composed of BRCA1, BARD1,
BRCA2, RAD51, BRCC3 and BRCC45 in addition to
other proteins [12], was reported to participate in the
DNA damage reponse illustrated above [13–15]. As one
of the subunits of BRCC, BRCC3 functions to counteract
Ubc13-RNF8 activity to provide a balanced level of ubi-
quitin near DNA lesions, which is essential for the re-
cruitment and dissociation of DNA repair proteins [15,
16]. Knocking down BRCC3 expression impairs the
DNA repair pathway [15, 17], resulting in the disruption
of G2/M checkpoint arrest [12] and increased cell apop-
tosis [17]. Furthermore, BRCC3 is overexpressed in the
vast majority of breast tumors [12]. Taken together, this
suggests that BRCC3 is accountable for cell radioresis-
tance and has potential clinical relevance in breast can-
cer. Thus, we hypothesize that BRCC3 plays a similar
role in NPC radioresistance and accounts for the poor
prognosis of NPC patients.
To study the clinical application value of BRCC3, we de-
termined the relationship between the BRCC3 expression
level and nasopharyngeal carcinoma patient survival.
Moreover, we investigated the contribution of BRCC3 to
radiation resistance in HNE1 and CNE2R cells, two hu-
man nasopharyngeal carcinoma cell lines that expressed a




This study was conducted on a total of 100 paraffin-
embedded NPC tissue samples obtained from patients
who were histologically and clinically diagnosed at the
Sun Yat-Sen University Cancer Center, China, between
1994 and 1999. Patient consent and approval from the
Institute Research Ethics Committee was obtained prior
to the use of these clinical materials for research pur-
poses. The clinical characteristics of the patients are
shown in Table 1.
Immunohistochemical staining (IHC)
IHC staining was performed using the Dako Envision sys-
tem (Dako, Carpinteria, CA) following the manufacturer’s
recommended protocols. All paraffin-embedded specimens
were cut into 4-μm sections and baked for 2 h at 65 °C. All
sections were deparaffinized with xylenes and rehydrated
with graded ethanol to distilled water and then submerged
in EDTA antigen retrieval buffer (pH 8.0) and microwaved
for antigen retrieval. After being treated with 0.3 % H2O2
for 15 min and normal goat serum for 30 min, the sections
were incubated with a BRCC3 antibody (1:200; PierceBiotechnology; PA5-20426) overnight at 4 °C. After
washing, the sections were incubated with a biotinyl-
ated anti-rabbit secondary antibody (Zymed) followed
by further incubation with streptavidin-horseradish per-
oxidase (Zymed) at 37 °C for 30 min. For the color re-
action, diaminobenzidine (DAB) was used.
We used the intensity and extent of the staining to as-
sess BRCC3. The entire tissue section was observed to
assign scores. The staining intensity was scored as 0 (no
staining), 1 (weak staining exhibited as light yellow), 2
(moderate staining exhibited as yellow brown), or 3
(strong staining exhibited as brown). The extent of stain-
ing was scored as 0 (0 %), 1 (1 to 25 %), 2 (26 to 50 %),
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centages of the positive staining areas in relation to the
whole carcinoma area or the entire section for the nor-
mal samples. The product of the intensity and extent
scores was used as the final staining score (0 to 12) for
BRCC3. For the purpose of statistical evaluation, tumors
having a final staining score of <4 were grouped into low
BRCC3 expression, and those with scores ≥4 were
grouped into high BRCC3 expression [18].
Cell culture, siRNA transfection, and IR
We received the identified CNE2 and CNE2R cells
(tested by analysis of the DNA microsatellite short tan-
dem repeats) from Professor Hui-ling Yang (Department
of Pathophysiology, Zhongshan School of Medicine, Sun
Yat-Sen University) [19, 20]. Other human NPC cell
lines (CNE1, SUNE1, SUNE2, HNE1, HONE1) were
maintained in Sun Yat-Sen University Cancer Center
[21, 22] and were not authenticated prior to this study.
All of the NPC cell lines were maintained in RPMI 1640
(Invitrogen, Carlsbad, CA) supplemented with 10 % fetal
bovine serum (FBS; Hyclone, Logan, UT), penicillin (100
units/ml), and streptomycin (100 units/ml) at 37 °C in a
humidified 5 % CO2 incubator.
For the BRCC3 depletion studies, NPC cells were plated
at a density of 3 × 105 cells/cm2. After reaching 30 % to
40 % confluence, cells were transfected with siRNA using
riboFECT™ CP and OPTI-MEM I reduced serum medium
(Invitrogen/Life Technologies, Inc., Carlsbad, CA) ac-
cording to the manufacturer’s protocol. The siRNA du-
plexes with the following sense and antisense sequences
were used, siRNA1: 5′-GAGGAAGGACCGAGUAGAA
dTdT (sense) and 5′-UUCUACUCG-GUCCUUCCUC
dTdT (antisense); siRNA2: 5′-AACAUCAACAUGUGA
AGGCdTdT(sense) and 5′-GCCUUCACAUGUUGAU
GUUdTdT(antisense) [13, 17]. All of the siRNA duplexes
were synthesized by RIBOBIO. Twenty-four hours after
transfection, the cells were irradiated using a R2000 X-ray
irradiator (1.1 Gy/min, 160 kV, 25 mA, 0.3 mm copper
filters).
Colony-forming assay
Cells were transfected with the indicated siRNAs, and
24 h later, they were trypsinized, seeded into 6-well
plates at different densities(100, 200, 103, 104cells for
0Gy, 2Gy, 4Gy, 6Gy groups separately) and X-ray irradi-
ated at defined doses. After 7–14 days of incubation, the
cultures were fixed and stained with Giemsa. Colonies
with more than 50 cells were scored as survivors. The
plating efficiency (PE) was calculated by dividing the
number of colonies counted by the number of cells plated.
The surviving fractions (SF) were then calculated by
dividing the PE by the PE of the non-irradiated control
[15, 23, 24]. Sensitization enhancement ratio(SER) wascalculated by division of SF2(surviving fractions at 2Gy).
Clonogenic survival curves were compared through the
extra sum-of-squares F test in GraphPad Prism [25].
Real-time RT-PCR
Total RNA from different NPC cell lines were extracted
with Trizol reagent (Invitrogen, Carlsbad,CA), then the
first-strand complementary DNA (cDNA) was synthe-
sized with 1 μg of total RNA. Realtime-PCR was per-
formed in triplicate by using the Absolute blue SYBER
green Rox mix (Thermo Scientific). PCR reaction and
data collection were conducted with an ABI PRISM
7900HT sequence detection system For normalization,
GAPDH was used as endogenous control. The primer
sequences are sense 5′-AATTTCTCCAGAGCAGCTGT
CTG, anti-sense 5′-CATGGC TTGTGTGCGAACAT
for BRCC3, and sense 5′-CTCCTCCTGTTCGACAGTC
AG C-3′, Antisense 5′- CCCAATACGACCAAATCCG
TT-3′ for GAPDH.
Western blot analysis
Western blot analysis was performed as described previ-
ously [18]. Briefly, total cellular proteins were extracted
with lysis buffer. The protein concentration was deter-
mined by BCA Protein Assay Kit (Beyotime Biotechnol-
ogy). Equal amounts of protein samples were loaded and
separated by SDS-PAGE gels, electrophoretically trans-
ferred to polyvinylidene difluoride membranes(Millipore).
The membrane was probed with primary antibody 4 °C
overnight and corresponding secondary antibody, The en-
hanced chemiluminescence was conducted according to
the manufacturer’s suggested protocols(Amersham Phar-
macia Biotech, Piscataway, NJ). Antibodies: BRCC3
(1:1000; Pierce Biotechnology; PA5-20426), CyclinB1
(1:2000; Cell Signaling; #4135), GAPDH (1:5000; Bioworld
Technology, Inc.; BSAP0063).
Immunofluorescence analysis
Cells were transfected with the indicated siRNAs and were
trypsinized 24 h after transfection, seeded on glass cover-
slips in a 24-well plate for 24 h, and irradiated at the indi-
cated doses. γ-H2AX immunofluorescence analysis was
carried out as described previously [24]. At 0 h, 0.5 h, 6 h,
12 h, and 24 h post irradiation, cells were fixed with
4 % paraformaldehyde (15 min, AppliChem, Darmstadt,
Germany) at room temperature (RT) and permeabilized
by the addition of 0.25 % Triton-X 100 in PBS for 15 min,
followed by blocking in 5 % bovine serum albumin (BSA)
in PBS for 30 min. Next, cells were incubated with
Phospho-Histone H2AX (Ser139) (20E3) rabbit mAb
(1:1000; Cell Signal Technology; #9718S), followed by the
appropriate Alexa 488-conjugated (green; Molecular
Probes) secondary antibodies Subsequently, nuclei were
counterstained with DAPI solution (Invitrogen) and
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boratories, Peterborough, UK). Images were taken using
an Olympus confocal imaging system (Olympus FV100)
for the quantification of γH2AX foci formation. At least
three independent experiments were performed for each
data point.
Cell cycle analysis
Cell cycle analysis was performed as described previously
[26]. Briefly, cells were harvested 24 h post-radiation by
trypsinization and washed with phosphate-buffered saline
(PBS). For cell cycle analysis, the cells were fixed with
70 % ethanol at -20 °C overnight. On the following day,
the fixed cells were washed with PBS, treated with RNase
A (50 μg/ml) in PBS at 37 °C for 20 min, and then mixed
with propidium iodide (PI, 50 μg/ml) for 30 min in the
dark. The stained cells were analyzed with fluorescence-
activated cell sorting (FACS) by flow cytometry (FACSCa-
libur, Becton Dickinson, Bedford, MA). The cell-cycle pro-
file was analyzed using the ModFit software (Becton
Dickinson). At least 10,000 cells in each sample were ana-
lyzed to obtain a measurable signal.
Statistical analysis
The Student t-test or Chi-square test was used to com-
pare the differences as appropriate. Survival analysis was
conducted by the Kaplan-Meier method and the log-
rank test. Multivariate analysis with Cox proportional
hazards model was employed to investigate independent
prognostic factors. A P-value of < 0.05 was considered
statistically significant. Statistical analysis was executed
by the SPSS software package (version 16.0, SPSS Inc) or
GraphPad prism 5.
Results
BRCC3 expression is inversely correlated with the survival
of NPC patients
To determine the impact of BRCC3 on survival, BRCC3
protein expression was determined by immunohisto-
chemistry in NPC patient tissues. The expression of
BRCC3 was primarily localized to the nucleus of cancer
cells (Fig. 1). The correlation between BRCC3 protein
levels and various clinicopathological factors are shown
in Table 1. No statistically significant correlations were
observed between the expression of BRCC3 and age at
diagnosis, gender, tumor size, or histological classifica-
tion. Statistically significant correlations between high
levels of BRCC3 expression were found with the clinical
stage and metastasis. Kaplan–Meier analysis revealed
that patients with a high expression of BRCC3 in NPC
tissues had a worse overall survival (OS) (Fig. 2a, log-
rank test: P < 0.001) than those with low BRCC3 expres-
sion. BRCC3 expression had no significant effect on the
10-year loco-regional relapse-free survival (LRRFS) ofNPC patients (Fig. 2b). Nevertheless, BRCC3 overex-
pression increased the risk of recurrence within three
years (Fig. 2b, P = 0.034).
Univariate analysis indicated that the clinical stage, T
classification, N classification, distant metastasis, relapse,
skull-base invasion and BRCC3 expression were statisti-
cally significant prognostic factors. However, the clinical
prognosis was not related to age, gender or histological
classification. Multivariate analysis including the BRCC3
expression level, T classification, N classification, distant
metastasis and skull-base invasion demonstrated that
the BRCC3 expression level (P = 0.01), distant metastasis
(P < 0.001), relapse (P = 0.001), and skull-base invasion
(P = 0.013) were independent prognostic factors for NPC
(Table 2). Thus, our findings indicate that the BRCC3
expression level, as an independent prognostic factor, is
inversely associated with the clinical prognosis of NPC.
BRCC3 is over-expressed in radioresistant NPC cells
To investigate the exact role of BRCC3 in NPC, we first
determined the BRCC3 expression levels in different
NPC cell lines by using Western blotting and real-time
PCR (Fig. 3a and b). Interestingly, both methods re-
vealed a relatively higher BRCC3 expression level in the
radioresistant cell lines CNE1 and HNE1 [27]. Based on
this, we determined the amount of BRCC3 expression in
CNE2 and resistant CNE2 (CNE2R) [19, 20]. Consistent
with the results above, we found a significantly upregu-
lated level of BRCC3 expression in CNE2R cells (Fig. 3c
and d). These results indicated that BRCC3 may partici-
pate in the regulation of NPC radiosensitivity.
BRCC3 knockdown sensitizes NPC cells to ionizing
radiation
Since high level of BRCC3 was correlated with poor
prognosis in NPC patients that treated by radiotherapy,
we sought to explore the association between BRCC3
expression and radiation resistance in vitro. We per-
formed in vitro silencing studies targeting BRCC3 in
HNE1 and CNE2R cell lines, which express relatively
high levels of BRCC3 (Fig. 3). The silencing efficiency
was confirmed by western-blotting (Fig. 4a). Following
transfection with control or BRCC3 siRNAs, we exposed
CNE2 cells, transfected HNE1 and CNE2R cells to ioniz-
ing radiation and compared the survival fractions using
colony formation assays, which revealed that CNE2R
cells were more resistant than CNE2 cell, BRCC3 knock-
down cells had significantly decreased survival fractions
compared to the corresponding control cells. In HNE1
cells SER of siRNA1 and siRNA2 was 1.26 and 1.21 sep-
arately; In CNE2R cells SER of siRNA1 and siRNA2 was
1.46 and 1.12 separately (Fig. 4b,c).
Next, we evaluated the DNA damage response
(DDR). BRCC3, as a Lys 63-linked ubiquitin-specific
Fig. 1 Immunohistochemistry staining of BRCC3 expression in nasopharyn-geal carcinoma tissues. BRCC3 expression was mainly localized within
the nuclei of cancer cells. a Tumor with low BRCC3 level (200×); c Tumor with high BRCC3 level (200×); b and d demonstrated the higher
magnification (400×) from the area of the box in (a) and (c) respectively. Low: low BRCC3 expression; High: high BRCC3 expression
Fig. 2 A negative correlation between BRCC3 expression and NPC patient survival. a Overall survival in NPC patients according to BRCC3
expression. Patients with high BRCC3 expression (n = 44) possessed with significantly poor overall survival compared with that of patients with
low BRCC3 expression (n = 56) (P < 0.001). Number of patients at risk at 0, 3, 5, 10 years is shown below the survival curves (L, patients with low
BRCC3 expression level; H, patients with high BRCC3 expression level). b Relapse Free Survival in NPC patients. The BRCC3 protein level was
inversely correlated with nasopharyngeal carcinoma patient 3-year loco-regional relapse-free survival (P = 0.034)
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Table 2 Univariate and Multivariate analysis of factors associated with overall survival
Variables Univariate analysis Multivariate analysis
HR 95 %CI Pa HR 95%CI Pa
Gender 0.725 0.320-1.642 0.440
Male vs Female
Age (years) 1.106 0.589-2.077 0.753
<45 vs≥ 45
Histological classification 1.602 0.568-4.516 0.373
Type II vs Type III
Clinical stage 3.402 1.651-7.007 0.001
I-II vs III-IV
T classification 1.886 0.999-3.558 0.050
T1-T2 vs T3-T4
N classification 2.328 1.233-4.395 0.009
N0 vs N1-N3
Distant metastasis 6.223 3.091-12.529 <0.001 7.026 2.898-17.037 <0.001
No vs Yes
Relapse 2.648 1.248-5.619 0.011 5.081 2.017-12.802 0.001
No vs Yes
Skull-based invasion 2.483 1.226-5.029 0.012 2.996 1.258-7.133 0.013
No vs Yes
Radiotherapy response 2.949 1.462-5.946 0.003
Sensitive vs Resistant
BRCC3 3.560 1.821-6.958 <0.001 2.674 1.270-5.630 0.010
Low vs High
Abbreviation: OS, overall survival; 95 % CI, 95 % confidence interval; HR, hazard ratio
a. Cox proportional hazards model
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role in the DDR, such as removing unnecessary DNA
repair factors after DSB repairs [15]. Therefore, to study
the effect of BRCC3 knockdown on the induction and
repair of DSBs in NPC cells, Cells were transfected with
BRCC3 or control siRNAs 24 h prior to irradiation
(2 Gy), and we conducted immunofluorescence before
and 0.5 h, 6 h, 12 h, 24 h after irradiaton to examine
the phosphorylation of H2A.X at Ser139 (γH2AX)
DNA repair foci in response to ionizing radiation. Our
results showed that the deficiency in BRCC3 did not re-
sult in a significant difference of DSB levels compared
to control cells before radiation and 0.5 h after radi-
ation. However, compared with control cells, a signifi-
cantly higher pecentage of γ-H2AX positive cells was
observed in BRCC3 knockdown cell lines HNE1 and
CNE2R 12 h (HNE1control: 44.17 ± 0.83; HNE1
siRNA1: 72.57 ± 4.0; HNE1 siRNA2: 70.39 ± 0.70;
CNE2R control: 42.65 ± 2.97; CNE2R siRNA1: 72.42 ±
3.0; CNE2R siRNA2: 66.16 ± 4.71) and 24 h (HNE1con-
trol: 35.08 ± 6.4; HNE1 siRNA1: 56.88 ± 4.97; HNE1
siRNA2: 58.95 ± 2.01; CNE2R control:19.38 ± 6.22;CNE2R siRNA1:45.40 ± 5.92; CNE2R siRNA2: 38.47 ±
6.37) after irradiation (Fig. 4d,e). These data indicated
that the loss of BRCC3 did not affect the induction of
γ-H2AX foci, but resulted in a significant delay of the
γ-H2AX foci absorption after exposure to ionizing radi-
ation in HNE1 or CNE2R cells, which implies the dis-
ruption of DSB repair. Thus, we concluded that BRCC3
knockdown observably sensitized NPC cell lines to
irradiation.
Depletion of BRCC3 results in G2/M cell cycle arrest
Cell cycle regulation was thought to be the foremost de-
terminant of ionizing radiation sensitivity [28]. Thus, we
used flow cytometric analysis to determine the effect of
BRCC3 on cell-cycle distribution after irradiation. Con-
trol and BRCC3 siRNA transfected NPC cells were ex-
posed to 0Gy or 4Gy iradiation, and the FACS analysis
was executed 24 h post- treatment. As seen in Fig. 5a
and b, radiation significantly disturbed the cell cycle pro-
gression and caused a dramatic increase of G2/M phase
populations in HNE1and CNE2R cells compared with
the uniradiated cells. No significant difference was noted
Fig. 3 High expression level of BRCC3 in radioresistant NPC cell
lines. a Western blot analysis of BRCC3 NPC cell lines; b Real-time
PCR analysis of BRCC3 protein in the same cell lines as described in
A. c Western blotting analysis of BRCC3 in CNE2 and CNE2R cells. d
Realtime PCR analysis of BRCC3 in CNE2 and CNE2R cells. T test was
used to compare the expression level, the asterisks indicate a significant
(***p< 0.001) difference
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profiles in the absence of ionizing radiation. In contrast,
24 h following a 4Gy dose of ionizing radiation, a signifi-
cantly greater percentage of BRCC3 knockdown cells
remained in the G2/M phase compared to control cells,
and correspondingly, a smaller percentage of BRCC3
knockdown cells were present in the G1 phase. This
suggested that BRCC3 knockdown enhanced the G2/M
cell cycle arrest induced by ionizing radiation.
We next sought to examine the expression of cell
cycle-related proteins. In mammals, cell-cycle progres-
sion is dependent on highly ordered events controlled by
the cyclins and cyclin-dependent kinases (Cdks) [29].
The cyclin B1/Cdk1 complex relocates in the matrix of
the mitochondria, and an increased influx of mitochon-
drial cyclin B1/Cdk1 was associated with the elevatedmitochondrial bioenergetics during the G2/M transition
[30]. The results of western blotting revealed that
cyclinB1 was significantly upregulated after 4Gy ionizing
radiation in HNE1 and CNE2R cells and that the deple-
tion of BRCC3 exacerbates the increase (Fig. 5c).
Discussion
In this study, we explored the effect of BRCC3 on NPC
patient survival and NPC cellular radiosensitivity. The
key findings of this work are described in the following:
First, it indicates a negative correlation between BRCC3
expression and NPC patient survival (Fig. 2); therefore,
BRCC3 may be a potential prognostic biomarker for
NPC. Second, it demonstrates that the expression of
BRCC3 was upregulated in both inherent (CNE1, HNE1)
and induced (CNE2R) radioresistant cell lines (Fig. 3),
which suggests that BRCC3 might be a critical factor in
the NPC radioresistance. Third, it reveals that knock-
down of BRCC3 expression through the use of siRNAs
sensitizes HNE1 and CNE2R cells to ionizing radiation,
impairs γH2AX foci absorption and induces G2/M cell
cycle arrest (Figs. 4 and 5), supporting a role for BRCC3
in cellular responsiveness to ionizing radiation, DNA re-
pair and G2/M checkpoint progression.
In addition to the effect of BRCC3 on patient overall
survival, interestingly, the present study discovered an
unforeseen correlation between BRCC3 expression and
metastasis (Table 1). A previous study demonstrated that
BRCC3 gene knockdown caused a decline in the migra-
tion and invasion capabilities of glioma cells [31]. Fur-
thermore, high expression of DNA repair pathways was
associated with metastasis in melanoma patients, and
BRCA1 showed a higher expression level in metastatic
patients [32]. Accordingly, in bladder carcinoma [33]
and breast cancer [34, 35] studies, the majority of the
significant repair genes were overexpressed in the pri-
mary tumors that are going to metastasize. The propor-
tion of significant repair genes that are overexpressed in
cancers that will metastasize reaches 90 % in melano-
mas, 82 % in bladder carcinomas, 80 % in the van’t Veer
breast cancer and 58 % in the breast cancers from
Wang’s study [35]. Consequently, the correlation be-
tween BRCC3 expression and metastasis in NPC pa-
tients is not surprising. The current study revealed the
relationship between BRCC3 and NPC metastasis. Fur-
ther research is necessary to determine the correlation.
In addition to the pertinent literature indicating the in-
volvement of BRCC3 in the DNA damage response, the
two important reasons attracting our attention to the
contribution of BRCC3 to NPC radioresistance is the
high BRCC3 level in 3-year LRRFS and the overexpres-
sion of BRCC3 in radioresistant NPC cell lines. The
BRCC3 level is upregulated in both inherent NPC cells
(CNE1, HNE1) and radiation induced resistant CNE2R
Fig. 4 Depletion of BRCC3 results in increased sensitivity to ionizing radiation. a Knockdown of BRCC3 was assessed by western-blotting (nc:
negative control siRNA; si1: siRNA1 target BRCC3; si2: siRNA2 target BRCC3). b HNE1 and CNE2R cells were transfected with siRNAs, 24 h later they
were seeded to 6-well plates and irradiated with different doses. Clones were stained and counted after 7-14 days. c Dose-survival curves of irradiated
HNE1 and CNE2R cells (range, 0-6Gy, SF: survival fractions, SER: radiation sensitization enhancement ratio). In HNE1 cells SER of si1 and si2 was 1.26
(p< 0.05) and 1.21 (p < 0.05) separately; In CNE2R cells SER of si1 and si2 was 1.46 (p< 0.01) and 1.12 (p < 0.05) separately. d Immunofluorescent staining
of γH2AX. HNE1 and CNE2R cells transfected with BRCC3 or control siRNA was exposed to 2Gy irradiation, and immunofluorescent staining of
γH2AX foci was conducted before and 0.5 h, 6 h, 12 h, 24 h after irradiation (e) Quantification of γH2AX foci formation. A positive cell was
determined by the presence of >10 foci/cell. The percentage of positive cells was compared by t-test. The asterisks indicate a significant
(*p < 0.05,**p < 0.01) difference
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pression sensitized the HNE1 and CNE2R cells to ioniz-
ing radiation (Fig. 4). This indicated that BRCC3 may be
a potential therapeutic target for not just the treatment-
naive patients, but for patients who suffered a relapse
after standardized treatment.
Although a variety of studies revealed that the deple-
tion of BRCC3 results in enhanced radiosensitivity
in vitro, the mechanisms of the increased radiosensitivity
caused by BRCC3 depletion have not yet been estab-
lished and could be partially due to its interaction withBRCA1. BRCC3 directly interacts with BRCA1 at the re-
gion encompassing amino acids 502 to 1054 [12], which
falls within the BRCA1 DNA-binding domain (amino
acids 452-1079). BRCC3 deficiency inhibits BRCA1
focus formation and disrupts the IR-induced phosphor-
ylation of BRCA1 [17] that may contribute to BRCA1-
dependent DSB repair. Another mechanism lies in the
BRCC3 de-ubiquitinating activity, which plays an im-
portant role for recruitment events in the repair of DSBs.
BRCC3 disruption has been reported to be associated with
increased 53BP1 and γH2AX foci accumulation after IR
Fig. 5 BRCC3 knockdown intensifies G2/M checkpoint arrest. a Cell-cycle profiles of HNE1 and CNE2R cells. Control and BRCC3 siRNA transfected
cells were treated with 0Gy or 4Gy, and the FACS analysis was executed 24 h post- irradiation.(nc: negative control siRNA; si1: siRNA1 target
BRCC3; si2: siRNA2 target BRCC3). b Quantification of A. BRCC3 inhibition caused an increased portion of G2/M phase in HNE1 and CNE2R cells.
c Western blot analysis of cyclinB1 24 h after 0Gy or 4Gy IR
Tu et al. Radiation Oncology  (2015) 10:123 Page 9 of 10[15]. This is consistent with our result indicating that
BRCC3 knockdown increased the persistence of γH2AX
foci positive cells 24 h after irradiation (Fig. 4d,e), which
indicated a delay of the DNA damage repair.
Regulation of the cell cycle may be another important
mechanism for radiosensitization, as supported by our
results that BRCC3 disruption increased cell-cycle arrest
in nasopharyngeal carcinoma cell lines (Fig. 5a, b). The
Cdk1-cyclin B complex is the main target molecule of
the G2/M cell cycle checkpoint [36, 37]. The results of
our study showed that BRCC3 knockdown upregulated
cyclinB1 expression after irradiation compared to the
control cells (Fig. 5c). In addition to BRCC3, the knock-
down of other BRCC complex subunits, such as BRCA1,
BRE, RAP80 and NBA1, also induced G2/M arrest [12,
38, 39], suggesting that the integrity of this complex is
vital for the G2/M transition. However, the subunits
may also play a separate role in the G2/M cell cycle
regulation. Cdk1 binds with RAP80 protein and medi-
ates its phosphorylation at an evolutionarily conserved
Ser-677 residue, which is important for RAP80 func-
tional sensitivity to IR and G2/M checkpoint control
[38]. Nevertheless, further studies are needed to deter-
mine the exact mechanism for the G2/M arrest induced
by BRCC3.
Conclusion
This study demonstrates that BRCC3 overexpression,
which contributes to a poorer prognosis in NPC pa-
tients, confers a stronger radiation resistance to NPCcells owing to more effective DNA damage repair and
cell cycle regulation. Thus, effectively inhibiting BRCC3
expression is a potential therapeutic strategy for sensitiz-
ing resistant NPC cells to radiation.
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